ClinicalTrials.gg
CompletedNCT01476189Updated Nov 24, 2014

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

A Phase 1 interventional study of Experimental paracetamol formulation and Marketed paracetamol in Healthy Subjects, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-24.

Sponsored by GlaxoSmithKline · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A repeat dose pharmacokinetic study investigating two paracetamol formulations

02

Conditions studied

  • Healthy Subjects

Keywords

  • pharmacokinetic
  • paracetamol
  • Healthy volunteer
  • steady state
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or physical examination.

Exclusion criteria

Exclusion Criteria:

  • Subject does not agree to refrain from alcohol consumption for the 10-day period prior to visit 2 and throughout the study.
  • Participation in another clinical study or receipt of an drug within 30 days of the screening visit.
  • Current (within 14 days of screening) or regular use of any prescription, over-the-counter drugs including paracetamol/acetaminophen, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing (e.g. barbiturates, theophylline, cimetidine, or erythromycin), excluding prescription , if applicable.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Experimental paracetamol formulation

    test formulation

    Drug: Experimental paracetamol formulation

  • Active comparator
    Marketed paracetamol

    Marketed paracetamol

    Drug: Marketed paracetamol

  • Active comparator
    Higher dose marketed paracetamol

    higher dose marketed paracetamol

    Drug: Higher dose marketed paracetamol

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence as measured by Area Under the Curve (AUC)

    Time frame: last 24 hours of dosing

Secondary outcomes

  1. Time duration at or above minimal therapeutic plasma paracetamol concentration

    Time frame: last 24 hours of dosing

  2. To assess pharmacokinetic parameters (Cmax, AUC, Tmax and Kel)

    Time frame: last 24 hours of dosing

  3. Adverse events

    Time frame: Baseline to 72 hours post dosing

07

Study locations

1 site
  • MDS Pharma Services NEBRASKA
    Lincoln, Nebraska 68501, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2011
First posted
Nov 22, 2011
Start
Nov 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Last update
Nov 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01476189
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Nov 2009
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Nov 24, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion